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Abstract 
Background: Non-cirrhotic intrahepatic portal hypertension (NCIPH), characterized by thrombotic 
microangiopathy of portal venous system, low ADAMTS13 (a disintegrin like and 
metalloproteinase with thrombospondin type 1 motifs–13) and high vWF (von-Willebrand factor) 
levels. This study aimed to screen for ADAMTS13 mutations, focusing on the CUB domain, in 
these patients.  
Methods: Prospectively recruited NCIPH patients and healthy volunteers underwent tests for 
plasma vWF-ADAMTS13 balance. Sanger sequencing of CUB domain of ADAMTS13 was done in 
a subset of the NCIPH patients and the detected mutation was screened for in all the study 
participants. Next generation sequencing of clinically relevant exome and liver immunostaining for 
ADAMTS13 was done in patient with detected ADAMTS13 mutation. 
Results: Plasma vWF-ADAMTS13 balance was significantly altered in 24 NCIPH patients (Child’s 
class A:23,B:1) as compared to 22 controls. On initial sequencing of the CUB domain (17 cases and 
3 controls), one NCIPH patient showed a rare mis-sense variant (SNV) at position c.3829C>T 
resulting in p.R1277W (rs14045669). Subsequent RFLP analysis targeted to R1277W variant, did 
not detect this in any other NCIPH patient, nor in any of the 22 controls.  
NCIPH patient with R1277W variant, had severe ADAMTS13 deficiency, consistently high vWF, 
other mis-sense SNVs in ADAMTS13, vWF and complement genes.  Immuno-staining of his liver 
biopsy revealed globules of ADAMTS13 within stellate cells. 
Conclusions: We report mis-sense variants in ADAMTS13, vWF and complement genes in a 
patient with NCIPH who had decreased secretion and activity of ADAMTS13 protein. Further 
studies are needed in NCIPH patients in this regard. 
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Introduction 
Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH) is characterised by occlusion of 
small intrahepatic portal vein radicles. Studies from India have shown that NCIPH is an ongoing 
problem especially in lower socioeconomic strata [1, 2]. We have demonstrated ADAMTS13 (a 
disintegrin like and metalloproteinase with thrombospondin type 1 motifs – 13) deficiency in 
patients with NCIPH despite preserved liver function [3, 4]. ADAMTS13, a vWF (von-Willebrand 
factor) cleaving protease secreted mainly from the hepatic stellate cells [5] and P-selectin, a protein 
anchoring vWF to endothelial surface are involved in primary hemostasis. In this study, we studied 
vWF-ADAMTS13 balance in these patients. 
ADAMTS13 gene is located on chromosome 9q34 (29 exons). ADAMTS13 protein consists of a 
number of domains including the metalloprotease domain (responsible for cleaving) at the N-
terminal and multiple CUB (complement C1r/C1s, urinary epidermal growth factor, and brain 
natriuretic peptide-1) domains at the C-terminal, which play important role in the binding of the 
protein to its substrate [6].  
We have noted lower plasma ADAMTS13 activity in NCIPH patients  when the ADAMTS13 
activity was assayed using the complete vWF molecule as a substrate (i.e. collagen binding assay) 
compared to  the activity using a synthetic vWF peptide substrate that contains the cleavage site (i.e. 
FRET or Fluorescence resonance transfer assay) [3]. We postulated that this phenomenon reflected 
defective binding of ADAMTS13 to vWF, a prerequisite for cleavage [7]. Mutations in the CUB 
domain of ADAMTS13 are associated with decreased activity and also defective secretion of 
ADAMTS13 from hepatic stellate cells [8]. In this study, we looked for mutations in the CUB 
domain of the ADAMTS13 gene (exons 26 and 27) in NCIPH patients as compared to healthy 
controls.  
The alternative complement pathway is activated by decreased expression of ADAMTS13 [9]. 
Unrestrained activation of alternative complement pathway is one of the mechanisms involved in 
the pathogenesis of thrombotic microangiopathy [9,10]. Localized intra-hepatic complement 
activation may also play a role in the pathogenesis of NCIPH. Over-activation of complement 
pathway is associated with familial mutations in genes involved in alternative/ lectin complement 
pathways. Recent reports describing mutations in KCNN3 [11] and DGUOK [12] genes in familial 
NCIPH patients reaffirm the pathogenic role of genetic factors in NCIPH.  
In this study, we carried out an evaluation for ADAMTS13- CUB domain mutations in a cohort of 
NCIPH patients. In a single NCIPH patient with ADAMTS13 CUB domain mutation, detailed 
genetic analysis (performed by next generation sequencing of clinically relevant exome) of 
ADAMTS13, vWF, alternative complement pathways and KCNN3/ DGUOK was performed. 
 
Methods : 
Objective 1 : Hospital based case-control study was performed to assess prevalence of mutation(s) 
in CUB domain of ADAMTS13 gene and also assess vWF-ADAMTS13 imbalance and plasma P-
selectin in NCIPH patients as compared to healthy volunteers.  
Objective 2 : In a NCIPH patient with ADAMTS13 CUB domain mutation, we performed the 
following tests :  
a. clinical exome sequencing using a custom capture kit to achieve high sequencing coverage  
for the target genes of interest. These genes included ADAMTS13 (37 Kb), vWF (176 Kb), 
alternative complement pathway genes [CFH (95 Kb), CFI (61 Kb), CFB (24 Kb), C3 (53 
Kb), CD46 (43 Kb)], lectin complement pathway gene {MBL2 (6.3 Kb)} and genes recently 
described in familial NCIPH {KCNN3 (173 Kb)and DGUOK (32 Kb)}. 
b. Immunostaining for ADAMTS13 on liver biopsy 
 
Case recruitment :  
Consecutive NCIPH patients visiting liver clinic were recruited as cases. Healthy volunteers served 
as healthy controls. NCIPH was diagnosed as per published criteria – all patients had 
gastroesophageal varices on endoscopy, patent portal vein and hepatic venous outflow tract on 
ultrasound doppler, an unyielding detailed evaluation for known etiologies of liver disease and liver 
biopsy showing the absence of advanced fibrosis and absence of findings suggesting alternate 
etiology, e.g. autoimmune hepatitis etc. Diseases, known to histologically mimic NCIPH (e.g. 
sarcoidosis, schistosomiasis etc.) were excluded [3].   
24 NCIPH patients were recruited for the study. The route of liver biopsy was - transjugular : 9 
patients; percutaneous : 7; per-operative : 8 {tru-cut and wedge biopsies of liver obtained during 
splenorenal shunt surgery (7) and splenectomy (1)}. On transjugular liver biopsy, 3 (2-7); median 
(range) cores of the liver with maximum size 11.5 (3-13) mm and containing 7 (5-13) portal tracts 
were obtained. Similarly, on percutaneous liver biopsy 2 (1-3) cores of the liver of maximum size 
15.5 (10-19) mm and containing 7 (5-19) portal tracts were obtained. On liver biopsy, 14 patients 
had mild portal fibrosis and 4 had no portal fibrosis, 5 had focal bridging fibrosis.  
Besides evaluation of the severity of liver disease in patients with NCIPH, all study participants 
underwent assays to determine the plasma ADAMTS13-vWF balance, plasma P-selectin (protein 
anchoring vWF to the endothelial surface) and also evaluation for mutation in CUB domain of 
ADAMTS13 gene. 
 
  
Assays of plasma levels of ADAMTS13, vWF and P-selectin in a cohort of NCIPH patients : 
Plasma levels of ADAMTS13, vWF and P-selectin were tested on citrated platelet poor plasma 
stored at -80°C until assay. ADAMTS13 FRET activity, vWF antigen/ acticity, and P-selectin 
concentrations were estimated by commercially available kits from American Diagnostica Inc, 
Hyphen BioMed and  R&D Systems respectively. 
ADAMTS13 activity was assessed by two methods- fluorescence resonance energy transfer (FRET) 
method which measures the increase in fluorescence when ADAMTS13 uncouples the recombinant 
-VWF86 ALEXA FRET substrate; and also by measuring residual collagen binding activity of 
purified vWF concentrate (in-house collagen binding assay, CBA) as was previously described [13].  
The manufacturer’s normal ranges for plasma ADAMTS13 antigen, ADAMTS13 FRET activity, 
vWF antigen, and P-selectin were: 740±110 ng/ml, 50%-150%, 0.5-1.5 IU/ml and 18-40 ng/ml 
respectively. vWF antigen and ADAMTS13 antigen were converted to a percentage of normal 
plasma for calculation of vWF:ADAMTS13 ratio. 
 
Sequencing the CUB domain of ADAMTS13 gene in a cohort of NCIPH patients : 
Genomic DNA was isolated from blood of 17 NCIPH patients as well as from 3 healthy controls 
using QIAGEN DNA extraction kit as described by the manufacturer. Genomic DNA (100ng) was 
utilized to amplify exons 26 and 27 pertaining to CUB domain of ADAMTS13 gene (9q34). The 
PCR reaction mixture (50µl) containing 25µl Taq DNA polymerase, 2x Master Mix Red, and 
forward (5’ ACA GGG TCC ACC CCT ACC T 3’) and reverse (5’ CCC AGT TCC TTC CAT CTC 
AG 3’) primers (4 pmol each) were used as described previously.  The PCR conditions were: Initial 
denaturation at 95°C for 2 min followed by 35 cycles of 95°C for 30 s, 56°C for 30 s, 72°C for 1 
min and final extension at 72°C for 5 min. The successful amplification was evident by visualization 
of a specific 901 bp PCR product on agarose gel electrophoresis after staining with ethidium 
bromide.  
Purified PCR products (901 bp) was sequenced both in the sense and anti-sense orientation using 
the Big Dye Terminator V3.1 cycle sequencing kit in a 3130 Genetic Analyzer from AB Applied 
Biosystems. The sequence was analyzed for mutations using the NovoSNP software. 
 
RFLP for the R1277W mutation in a cohort of NCIPH patients : 
RFLP for the detected ADAMTS13-CUB domain variant (R1277W) was performed in all 24 
NCIPH patients and 22 healthy controls. PCR products were digested with the restriction 
endonuclease BalI to identify R1277W variant. Purified PCR product (~ 1 µg) was digested by BalI 
(2 units) at 37°C for 2 hours and the digested products were separated by agarose gel (2% (W/V)) 
electrophoresis. 
 
Clinical Exome Sequencing and immunostaining of liver biopsy for ADAMTS13 in one NCIPH 
patient with ADAMTS13 R1277W variant 
To preclude other causative mutations, clinical exome sequencing was carried out in one NCIPH 
patient (who had ADAMTS13 R1277W variant). Exome capture was performed on 50ng of 
genomic DNA sample using Nextera Rapid Capture custom enrichment. The library was sequenced 
at a mean coverage of >80-100X on Illumina sequencing platform. The sequences obtained were 
aligned to the human reference genome (GRCh37/hg19) using BWA tool and the variant calling 
was performed using GATK-Lite based tools. Further, the annotation of variants identified was 
carried out against the Ensemble release 75 gene model.  98% of the coding region of ADAMST13 
was covered by the sequencing process with 96.1% of the reads of quality ≥ Q30. Further, 
validation of the sequencing data analysis to identify variations in target genes of interest pertaining 
to ADAMTS13-vWF axis (ADAMTS13, vWF), alternative/ lectin complement pathways (CFH, 
CD46,CFI, CFB,C3, MBL2) and genes recently described associated with familial NCIPH ( KCNN3 
and DGUOK) was carried out using DNA Star software (DNASTAR, Inc. Madison, Wisconsin, 
USA). 
Indirect immunofluorescence technique was used to immunostain the liver biopsy of this NCIPH 
patient using a commercial rabbit polyclonal antibody to ADAMTS13 (H-300, Santa-Cruz 
Biotechnology, Inc). The nuclei were labelled by 4',6-diamidino-2-phenylindole(DAPI) and stellate 
cells were stained with glial fibrillary acidic protein (GFAP). 
 
Statistical analysis : 
Variables were expressed as numbers (percentage) or median (range) as appropriate. Non-
parametric tests (Mann-Whitney U, Wilcoxon signed ranks test, Fisher exact test or Chi-square test) 
were used for comparison and a p-value of ≤0.05 was considered as statistically significant. The 
study was approved by the institutional ethics committee.  
 
Results  
Twenty four   NCIPH patients and 22 healthy controls were recruited for this study. Table 1 depicts 
the regional distribution, demographics and baseline characteristics of the study participants. All 
NCIPH patients were in Child’s class A (23 patients) or B (1 patient). There was no family history 
of liver disease in NCIPH patients.  
Twenty one of the 24 NCIPH patients had thrombocytopenia – severe (<50000/cmm) : 6; moderate 
(50,000/cmm-75,000/cmm) :4; and mild (75,000/cmm-1,50,000/cmm) : 11.  Three of the 20 (15%) 
patients tested had low serum vitamin B12 levels (<200 pg/ml).  Hepatic venous pressure gradient 
measured in 11 NCIPH patients was 7 (5-18) mm Hg; median (range). In two patients, HVPG was 
≤5 mm Hg. One NCIPH patient each had associated celiac disease and arsenicosis. 
 
  
Plasma ADAMTS13-vWF levels in cohort of NCIPH patients and in controls :  
vWF antigen in 23 NCIPH patients (1.8, 1-5.3 IU/ml; median, range) was significantly higher than 
in 18 healthy controls (0.9, 0.4-1.66 IU/ml; p-value <0.001); figure 1.  
Plasma ADAMTS13 antigen in 15 NCIPH patients (486, 239-614 ng/ml; median, range) was 
significantly lower than in 18 healthy controls (753, 394-107 ng/ml; p-value<0.001). Figure 1 also 
depicts the deranged vWF:ADAMTS13 ratio in NCIPH patients (2.4, 1.2-6.5) as compared to 
healthy controls (0.9, 0.5-1.8; p-value:<0.001).  
Figure 2 depicts the plasma ADAMTS13 activity as assayed by FRET and collagen binding assays 
in NCIPH patients (76%, 39-136% and 66%, 10%-105%) as compared to healthy controls (110%, 
63%-161% and 104%, 83%-122%) respectively. In both these assays, the ADAMTS13 activity was 
significantly lower in NCIPH patients (p-value: 0.008 and p-value <0.001) as compared to healthy 
controls. In NCIPH patients, there was a trend to lower ADAMTS13 activity by collagen binding 
assay (CBA) as compared to ADAMTS13 activity by FRET assay. 
One NCIPH patient (Child’s score : 6) had severe ADAMTS13 deficiency (ADAMTS13 activity by 
CBA <10%) and six NCIPH patients (Child’s score: 5 in four patients and Child’s score: 6 in 2 
patients) had a mild ADAMTS13 deficiency (ADAMST13 activity by CBA ≤ 55%). None of the 
healthy controls had deficient ADAMTS13 activity by CBA. 
 
P-selectin levels in cohort of NCIPH patients and in controls  
Plasma P-selectin levels were similar in 15 NCIPH patients (39 ng/ml, 5-144 ng/ml; median, range) 
and 9 healthy controls (34 ng/ml, 8-41 ng/ml; p-value : 0.5). 7/15 NCIPH patients had high plasma 
P-selectin levels, i.e. > 40 ng/ml as compared to 1/9 healthy controls (p-value : 0.2).  
 
  
Mutation analysis in the CUB domain of ADAMTS13 gene in cohort of NCIPH patients 
Sequencing of the CUB domain was done in 17 NCIPH patients and 3 healthy controls. One NCIPH 
patient showed a rare nucleotide change at position c.3829C>T resulting in p.R1277W 
(rs14045669).  
We further performed BalI RFLP analysis targeted to R1277W variant detection in all 24 NCIPH 
patients and 22 healthy controls (including the subjects in whom sequencing was done). Except for 
one NCIPH patient with R1277W variant on sequencing, no other subjects had this variant, figure 3.  
 
Clinical exome sequencing variant analysis in one NCIPH patient with ADAMTS13 R1277W 
variant : 
No reported pathogenic variants were identified by clinical exome sequencing in this patient. 
However, further analysis of the clinical exome sequence data for the target genes of interest 
detected the presence of several nucleotide changes including heterozygous missense variants 
(p.R1277W & p.Q448E) in ADAMTS13 gene and also in CFI, CFB, CFH and vWF genes (Table 2). 
All observed missense variants were predicted to be polymorphisms or benign by bio-informatic 
tools Polyphen-2, SIFT and Mutation taster (www.mutationtaster.org).   Only R1277W variant 
(dbSNP rs140450669) in ADAMTS13 gene was found to be rare and was reported in ExAc 
database (Exome Aggregation consortium) with an allelic frequency of 0.017% in South Asians and 
0.002% in Europeans. Details of the non-synonymous variants are given in Table 2. The list of all 
variants in the genes of interest is provided as supplementary material. 
 
Immunostaining of liver biopsy in one NCIPH patient with ADAMTS13 R1277W variant : 
On immunostaining of normal liver tissue, we demonstrated co-localisation of ADAMTS13 and 
GFAP (which stains liver stellate cells,). On studying the ADAMTS13 immuno-stained liver biopsy 
slides, on light microscopy, unlike normal/ cirrhotic control, more punctate and diffuse ADAMTS13 
staining, and under high power, globules of ADAMTS13 were seen in stellate cells (Figure 4).  
 
Clinical details of NCIPH patient with ADAMTS13 R1277W variant: 
21 year old male, born to non-consanguineous parentage, belonging to lower socioeconomic class 
(as assessed by modified Kuppuswamy score), residing in northern India presented with 
splenomegaly since 10 years of age and hematemesis at the age of 17 years. He had no family 
history of similar illness. He underwent proximal splenorenal shunt surgery in 2012. Per-operative 
liver biopsy showed mild portal fibrosis. He developed glomerulonephritis (renal biopsy suggesting 
C3 nephritis) 15 months after the shunt surgery and was treated unsuccessfully with steroids. He 
developed secondary portal vein thrombosis and had worsening kidney function on follow-up. He 
suffered from two episodes of spontaneous bacterial peritonitis and subsequently was on 
maintenance hemodialysis from 2.5 years after the shunt surgery. Repeat kidney biopsy revealed 
diffuse, proliferative sclerosing glomerulonephritis with deposits of IgA, IgG, IgM and C3.  
He had low ADAMTS13 activity (lowest level CBA:10%; FRET : 68.3%) and high vWF antigen 
levels at the initial visit (5.33 IU/ml) in the plasma.  The subsequent ADAMTS13 levels were within 
normal range, but vWF activity assessed by collagen binding assay remained high {2.9xULN (2.6-
3.5xULN); median, range}, Table 3. Plasma P-selectin levels were high (100 ng/ml). He had platelet 
counts in the normal range (post-splenectomy status) and had no features suggesting 
microangiopathy (like schistocytes in peripheral blood smear) in the systemic circulation. Total 
complement activity was low (60%, normal: 80-96%) with low C3 (76 mg/dl, normal: 90-180 
mg/dl) and preserved C4 (11.4 mg/dl, normal: 10-140 mg/dl); suggesting possible activation of the 
alternative complement pathway. There was no inflammation on duodenal biopsy and anti-tissue 
transglutaminase antibody was negative. There were no skin changes suggesting arsenicosis, but 
nail arsenic levels were not tested. 
 
Discussion : 
NCIPH is a relatively common cause of unexplained portal hypertension in India [1,2]. Our 
two previous reports from India and UK have demonstrated low ADAMTS13 activity, 
especially with collagen binding activity assay, in NCIPH patients despite preserved liver 
function. The present study also reiterates this finding, with all three studies demonstrating 
lower activity with ADAMTS13-CBA assay (activity against the complete vWF molecule) 
compared to ADAMTS13-FRET assay (activity against vWF peptide fragment having the 
cleaving site). This suggests relatively preserved specific vWF cleaving activity of 
ADAMTS13, prompting us to embark on a study to assess exons pertaining to CUB domain 
(thought to be responsible for the initial binding of ADAMTS13 to vWF) of ADAMTS13 
gene.  
In this study, of the 24 NCIPH patients, we found mutations in the CUB domain of 
ADAMTS13 in a single patient. This patient had severely deficient ADAMTS13 collagen 
binding activity (on single occasion), consistently raised vWF and retention of ADAMTS13 
globules in the hepatic stellate cells. Immunostaining of liver biopsy strongly suggests a 
defect in ADAMTS13 secretion. His plasma vWF activity, on four occasions, was elevated 
2.6-3.5 times the upper limit of normal. Hence, this rare variant (p.R1277W) in exon 27, 
pertaining to CUB domain of ADAMTS13 gene might have a role in defective ADAMTS13 
protein secretion which has to be functionally validated. Deletion of exon 27 (pertaining to 
CUB domain) of ADAMTS13 has also been noted in one patient with hereditary TTP [14]. 
Neither the other NCIPH patients nor the healthy controls had any detectable mutation in the 
ADAMTS13 CUB domain. The functional significance of this mutation needs to be further 
characterised.   
In order to understand the possibility of other genes involvement in NCIPH, we performed 
clinical exome sequencing in this NCIPH patient with ADAMTS13 CUB domain 
(p.R1277W) mutation. Another missense variant in ADAMTS13 gene Q448E (rs2301612; 
cysteine rich region) was also identified in this patient. This SNP has been previously 
reported in families with congenital thrombotic thrombocytopenic purpura (TTP) [15]. Allele 
frequency of rs2301612 was 19% (tested in 364 healthy subjects from Japan [16]). The 
frequency of this polymorphism in Indian population needs to be characterised. Though in the 
study by Kokame et al [15], no functional impact of this mutation (rs2301612) was noted on 
vWF cleaving activity, it has been shown that along with other ADAMTS13 mutations it can 
modulate ADAMTS13 protein expression and activity [17]. This variation has been shown to 
have a deleterious impact on other vascular pathology e.g. cerebral aneurysms [17].  
Altered vWF-ADAMTS13 balance is noted in advanced stages of cirrhosis and may be 
involved in the progression of disease [18-20]. In NCIPH patients we have noted deficient 
ADAMTS13 activity in patients with preserved liver function, suggesting a role in the 
pathogenesis of intrahepatic portal venous occlusion [3,4].  
Table 2 lists the various non-synonymous variants noted in the NCIPH patient on targeted 
exome sequencing of the genes of interest (pertaining to ADAMTS13-vWF, alternative and 
lectin complement pathways, DGUOK and KCNN3). Besides R1277W variation, there were 
rare variants (minor allele frequency of <0.5% [21]) noted in alternative complement 
pathways (CFI and CFH). Though none of these variants have previously been associated 
with NCIPH, the effect of combined burden of these variants is unclear. It is expected that 
rare variants are more likely to confer risks for a disease process and same needs to be further 
studied [22]. 
The other variants in CFH and CFB (rs1061170 and rs12614 respectively) have been 
previously reported with uncertain significance in atypical haemolytic uremic syndrome, 
another form of thrombotic microangiopathy. Previous studies also describe other variations 
in complement genes in patients with congenital TTP and haemolytic uremic syndrome [23].  
Acquired or inherited deficiency of ADAMTS13 results in accumulation of ultra-large vWF 
multimers, which in turn predisposes platelet adhesion to the endothelium [24-26]. 
ADAMTS13 deficiency is implicated in TTP and its role in various other thrombotic 
conditions is under study [27,28]. Genetic variations in ADAMTS13 can result in inherited 
form of severe TTP (Upshaw Schulman Syndrome) or may result in partial ADAMTS13 
activity loss predisposing to various thrombotic events [8,29-32]. 
ADAMTS13 deficiency may trigger complement activation in patients with thrombotic 
microangiopathy [9]. In addition to low ADAMTS13, activation of alternative complement 
pathway is an important mechanism for thrombotic microangiopathy.  
Also, there were recent reports of single gene mutations in DGUOK [12] and KCNN3 [11], 
implicated in familial NCIPH inherited in autosomal recessive/ dominant manner 
respectively. We did not find any variations in these genes in a single NCIPH patient.  
Unlike the autosomal dominant/ recessive inheritance noted in some of the studies, none of 
our NCIPH patients in this study had a family history of similar liver disease. This suggests 
that NCIPH, in most patients, is a complex disorder, where a genetically predisposed 
individual when challenged by an environmental risk factor, develops localised portal 
vasculopathy. Thus, either a shared genetic predisposition or a shared environmental insult 
could be responsible for the increased prevalence of NCIPH in India and other developing 
countries [33]. As the pathology is limited to portal microcirculation, in previous studies we 
looked at the role of gut in the pathogenesis of NCIPH. There was an increased prevalence of 
non-specific gut inflammation [34], celiac disease, and gut derived toxins (arsenicosis) [35] 
in these patients. In the present study, one NCIPH patient each had arsenicosis and celiac 
disease.  
As in our previous report [36], in this study also 15% of NCIPH patients had low vitamin 
B12 levels. In India, with endemic vitamin B12 deficiency, presence of vitamin B12 
deficiency in patients with unexplained portal hypertension is a marker of absence of 
advanced fibrosis and NCIPH [37]. It is unclear if this is association has any causative 
implications in pathogenesis of NCIPH. 
Worsening vWF-ADAMT13 imbalance is noted with advancing stages of cirrhosis [19,20]. 
This may contribute to focal parenchymal extinction in the liver noted in these patients and 
consequently important in the progression of disease [38]. Altered vWF-ADAMTS13 balance 
may also play a role in pro-thrombotic mileu noted in cirrhotics [39]. There is scope for wide 
ranging therapeutic potential targeting the vWF-ADAMTS13 imbalance to treat NCIPH in 
particular and portal hypertension in general [40].   
Thus, in our study we demonstrate missense variants in ADAMTS13, vWF and complement 
genes in a single patient with NCIPH, associated with decreased secretion and activity of 
ADAMTS13 protein. Further research in this area is warranted. 
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Figure legends : 
Figure 1: vWF (panel A), ADAMTS13 (panel B) antigen and vWF:ADAMTS13 ratio (panel 
C) in patients with NCIPH as compared to healthy controls. The horizontal line in panel A 
and B depicts the upper normal limit of vWF and lower normal limit of ADAMTS13 antigen 
respectively. 
 
N.B: vWF concentrations were available in 15 NCIPH patients and 18 healthy controls, ADAMTS13 
concentrations were available in 23 NCIPH patients and 18 healthy controls. 
 
Figure 2 : Plasma ADAMTS13 activity assayed by FRET (fluorescence resonance energy transfer) 
assay and collagen binding assay (CBA) in NCIPH patients as compared to healthy controls. The 
ADAMTS13 values for the patient with R1227W mutation in ADAMTS13 CUB domain are 
marked with asterisk (*).  
N.B: FRET available in 23 NCIPH patients and 18 healthy controls, CBA available in 20 NCIPH patients and 
13 healthy controls. 
 
Figure 3: Restriction fragment length polymorphism on the ADAMTS13 CUB domain PCR 
product (901 bp). The mutation R1227W created a new restriction site for DNA restriction 
enzyme BalI, resulting in extra bands in one NCIPH patient 
 
Figure 4 : Indirect immunofluorescence of liver biopsy. Panel A and B shown co-localisation 
of stellate cell marker GFAP (white) and ADAMTS13 (red) in normal liver. Panels C and F 
(normal), panels D and G (cirrhotic control) and panels E and H (NCIPH patient with 
R1277W mutation) show more diffuse and punctate staining as well as ADAMTS13 globules 
in the higher magnification in NCIPH patient. Similar globules were not seen in normal/ 
cirrhotic liver biopsy. 
  
Table 1 : Demographics and baseline disease status in study participants.  
Parameters# NCIPH  
(n=24) 
Healthy controls  
(n=22) 
Age (years) 37 (17-66) 33 (28-61) 
Sex (M:F) 20:4 17:3 
Regional distribution (E:S:W:N:F)* 9:11:0:1:3 1:18:0:1:0 
Serum bilirubin (mg%) 1 (0.3-4.9) - 
Serum Albumin (mg%) 3.8 (2.5-4.9) - 
Serum Creatinine (mg%) 0.9 (0.6-2.5) - 
International Normalised Ratio 1.1 (1-1.2) - 
Child’s score 5 (5-7) - 
Hemoglobin (g%) 11.9 (8.4-14.6) - 
Platelet count (x105/ cmm) 0.9 (0.05-2.33) - 
Serum Vitamin B12 pg/ml (n=20)@ 411 (150-1110)  - 
#All values are depicted as numbers or median (range); *Regional distribution :: E: Eastern India; S 
: Southern India; W: Western India; N: Northern India; F: Foreign nationals; all from Bangladesh. 
@Serum Vitamin B12 normal range: 200-950pg/ml; 3 patients had <200 pg/ml. 
 
 
  
 Table 2: List of non-synonymous variants in the targeted sequencing of the genes of interest  
Gene DNA Change 
Amino Acid 
Change 
dbSNP ID 
MAF 
(ExAC) 
PP2 
SIF
T 
MT Disease association 
ADAMTS1
3 
c.1342C>G p.Q448E 2301612 0.453 BEN Tol Poly 
Congenital Thrombotic 
Thrombocytopenic Purpura 
ADAMTS1
3 
c.3829C>T p.R1277W 140450669 0.00005 BEN Tol Poly - 
VWF c.2555A>G p.Q852R 216321 0.1008 BEN Tol Poly 
von Willebrand Disease 
(Type 2N) 
VWF c.2365A>G p.T789A, 1063856 0.3232 BEN Tol Poly - 
VWF c.1451A>G p.H484R, 1800378 0.3788 BEN Tol Poly - 
CFB c.94C>T p.R32W 12614 0.1312 
POS 
DAM 
Del Poly Chronic Hepatitis B 
CFI c.898A>G p.T300A 11098044 0.0094 BEN Tol Poly - 
CFH c.1204C>T p.H402Y, 1061170 0.3279 BEN Tol Poly 
Age related macular 
degeneration 
CFH c.2821G>T p.V941F, 529492401 0.0004   Poly - 
 
MAF- Minor allele frequency, PP2-Polyphen 2, BEN-Benign, POS DAM-Possibly Damaging,  SIFT- Sorting Intolerant from Tolerant, Tol- 
Tolerable,  Del-Deleterious, MT-Mutation Taster, Poly-Polymorphism 
ADAMTS13: a disintegrin like and metalloproteinase with thrombospondin type 1 motifs – 13; vWF: von-Willebrand factor; CFB: 
Complement factor B; CFI : Complement factor I; CFH: Complement factor H 
  
 Table 3 : Laboratory values of NCIPH patient with detectable R1277W variation in CUB domain of 
ADAMTS13 gene 
 
Time Mar ‘14 Jul ‘14 Nov ‘14 Feb ‘15 
Plasma ADAMTS13-CBA (%)* <10 72 77 87 
Plasma vWF-CBA (%)* 421 495 379 565 
Platelets (X105/cmm) 3.41 1.87  1.31 
Child’s score 8 6 6 7 
Serum bilirubin (mg/dl) 0.4 0.5 0.46 0.27 
Serum albumin (mg/dl) 1.5 2.8 3.1 2.2 
MELD score 13 13  15 
*Normal ranges - ADAMTS13-CBA: 50%-150%; vWF-CBA: 50%-160% 
ADAMTS13: a disintegrin like and metalloproteinase with thrombospondin type 1 motifs – 13; vWF: von-Willebrand factor; CBA: 
Collagen binding activity assay; MELD : Model for end-stage liver disease 
 
  
  
  
  
Figure 2 : Plasma ADAMTS13 activity assayed by FRET (fluorescence resonance energy transfer) 
assay and collagen binding assay (CBA) in NCIPH patients as compared to healthy controls. The 
ADAMTS13 values for the patient with R1227W mutation in ADAMTS13 CUB domain are 
marked with asterisk (*).  
N.B: FRET available in 23 NCIPH patients and 18 healthy controls, CBA available in 20 NCIPH patients and 13 
healthy controls.  
 
 
  
Figure 3: Restriction fragment length polymorphism on the ADAMTS13 CUB domain PCR 
product (901 bp). The mutation R1227W created a new restriction site for DNA restriction enzyme 
BalI, resulting in extra bands in one NCIPH patient 
 
 
  
  
Figure 4 : Indirect immunofluorescence of liver biopsy. Panel A and B shown co-localisation 
of stellate cell marker GFAP (white) and ADAMTS13 (red) in normal liver. Panels C and F 
(normal), panels D and G (cirrhotic control) and panels E and H (NCIPH patient with 
R1277W mutation) show more diffuse and punctate staining as well as ADAMTS13 globules 
in the higher magnification in NCIPH patient. Similar globules were not seen in normal/ 
cirrhotic liver biopsy.  
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